Concomitant use with apomorphine hydrochloride is contraindicated due to reports of profound hypotension and loss of consciousness.
Source: NLP:apomorphine hydrochloride
Brand names: Sustol
Serotonin-3 Receptor Antagonist · Serotonin 3 Receptor Antagonists
Route: Subcutaneous
Contraindications
4 CONTRAINDICATIONS SUSTOL is contraindicated in patients with hypersensitivity to granisetron, any of the components of SUSTOL, or to any of the other 5-HT 3 receptor antagonists [see Warnings and Precautions ( 5.3 ), Description ( 11 )] . Hypersensitivity to granisetron, any of the components of SUSTOL, or to any of the other 5-HT 3 receptor antagonists. ( 4 , 5.3 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary There are no available data on the use of SUSTOL in pregnant women. Limited published data on granisetron use during pregnancy are not sufficient to inform a drug-associated risk. In animal reproduction studies, no adverse developmental effects were observed in pregnant rats and rabbits administered granisetron hydrochloride during organogenesis at intravenous doses up to 61 times and 41 times respectively the maximum recommended human dose (MRHD) of SUSTOL 10 mg/week [see Data] . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data Reproduction studies with granisetron hydrochloride have been performed in pregnant rats following administration during the period of organogenesis at intravenous doses up to 9 mg/kg/day (approximately 61 times the maximum recommended human dose (MRHD) of SUSTOL 10 mg/week, based on body surface area) and oral doses up to 125 mg/kg/day (approximately 851 times the MRHD of SUSTOL 10 mg/week, based on body surface area). Reproduction studies have been performed in pregnant rabbits in which granisetron hydrochloride was administered during the period of organogenesis at intravenous doses up to 3 mg/kg/day (approximately 41 times the MRHD of SUSTOL 10 mg/week, based on body surface area) and at oral doses up to 32 mg/kg/day (approximately 436 times the MRHD of SUSTOL 10 mg/week, based on body surface area). These studies did not reveal any evidence of impaired fertility or harm to the fetus due to granisetron hydrochloride. Reproduction studies with the polymer vehicle for SUSTOL have been performed in pregnant rats and rabbits following administration of the polymer vehicle duri
4 interactions on record
Concomitant use with apomorphine hydrochloride is contraindicated due to reports of profound hypotension and loss of consciousness.
Source: NLP:apomorphine hydrochloride
Anti-emetic that prolongs QT interval; should be avoided with toremifene citrate or requires close monitoring.
Source: NLP:toremifene citrate
QT interval prolonging drug. Coadministration with VANFLYTA may further increase incidence of QT prolongation. More frequent ECG monitoring recommended.
Source: NLP:quizartinib
Concomitant use may cause serotonin syndrome including altered mental status, autonomic instability, and neuromuscular symptoms. Monitor for emergence of serotonin syndrome.
Source: NLP:granisetron